Report overview
The major advantage of Flu RNA Vaccines is that scientist need not to use the live cells for the vaccine preparation as such the RNA can be produced in the laboratory from a DNA template using readily available materials which can be a easy and fast weapon to fight against the new outbreaks and the existing infectious diseases.
This report aims to provide a comprehensive presentation of the global market for Flu RNA Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Flu RNA Vaccines. This report contains market size and forecasts of Flu RNA Vaccines in global, including the following market information:
Global Flu RNA Vaccines Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Flu RNA Vaccines Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Flu RNA Vaccines companies in 2022 (%)
The global Flu RNA Vaccines market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Non-Replicating mRNA Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Flu RNA Vaccines include Sanofi Pasteur Inc., AstraZeneca, CSL Ltd., Abbott, GlaxoSmithKline Plc., Serum Institute of India Pvt. Ltd., Pfizer, BioNTech and F.Hoffman La Roche Ltd, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Flu RNA Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Flu RNA Vaccines Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Flu RNA Vaccines Market Segment Percentages, by Type, 2022 (%)
Non-Replicating mRNA
In Vivo Self-Replicating mRNA
In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
Others
Global Flu RNA Vaccines Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Flu RNA Vaccines Market Segment Percentages, by Application, 2022 (%)
Hospitals
Vaccination Center
Specialized Clinics
Hospital Pharmacy
Others
Global Flu RNA Vaccines Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Flu RNA Vaccines Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Flu RNA Vaccines revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Flu RNA Vaccines revenues share in global market, 2022 (%)
Key companies Flu RNA Vaccines sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Flu RNA Vaccines sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi Pasteur Inc.
AstraZeneca
CSL Ltd.
Abbott
GlaxoSmithKline Plc.
Serum Institute of India Pvt. Ltd.
Pfizer
BioNTech
F.Hoffman La Roche Ltd
Novartis
Sinnovac Biotech Ltd
Moderna Therapeutics
CureVac
Outline of Major Chapters:
Chapter 1: Introduces the definition of Flu RNA Vaccines, market overview.
Chapter 2: Global Flu RNA Vaccines market size in revenue and volume.
Chapter 3: Detailed analysis of Flu RNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Flu RNA Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Flu RNA Vaccines capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
